Unpublished data from our group and a recent publication by Hasegewa and co-workers support the notion that Tregs in MLL-AF9 mice limit anti-leukemic immunity only in a situation with minimal leukemia load but not in an advanced stage of the disease (33). Here, KMT2A is linked to leukemia.